Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
February 27 2024 - 10:30AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2024
Commission File No. 001-35193
Grifols, S.A.
(Translation of registrant’s name into English)
Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan
Sant Cugat del Valles 08174
Barcelona, Spain
(Address of registrant’s principal executive
office)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F x
Form 40-F ¨
Grifols, S.A.
TABLE OF CONTENTS
| Grifols, S.A.
Avinguda de la Generalitat 152-158
08174 Sant Cugat del Vallès
Barcelona - ESPAÑA
Tel. [34] 935 710 500
Fax [34] 935 710 267
www.grifols.com
Pursuant to the provisions of article 227 of the Law 6/2023, of 17 March, on Securities Markets
and Investment Services, Grifols, S.A. ("Grifols" or the "Company") hereby informs about the
following
OTHER RELEVANT INFORMATION
Following the Other Relevant Information communicated by the Company on 5 February 2024,
Grifols' Board of Directors informs that, in its meeting held on 26 February 2024, it has
unanimously agreed to appoint Mr. Jose Ignacio (Nacho) Abia as a new member of the Board,
following the previous favourable report from the Appointments and Remuneration Committee,
through the co-option procedure and temporally with the category of "other external". Further,
Mr. Nacho Abia is appointed as CEO with effect from 1 April 2024, at which time his category
will be "executive" director.
As previously informed, Mr. Nacho Abia is an accomplished senior executive with more than
two decades of international management experience at publicly traded life-science and medical-technology companies. All his professional experience has provided him with great knowledge
in corporate strategy and planning, business and product development, regulatory, as well as
medical and clinical affairs. Further, he has been responsible for multiple international M&A
transactions.
Likewise, he serves in the Board of Directors of AdvaMed (Advanced Medical Technology
Association) in the United States, in the Board of Directors of the US-Spain Chamber of
Commerce and is also member of the Board of Trustees of the Lehigh Valley Health Network, a
hospital system composed of 13 hospitals and multiple care centres in Pennsylvania. In the past,
he was member of the Board of Directors of Evident Corporation, a company in the field of life
sciences and industrial solutions. .
The Board of Directors will propose to the next General Shareholders' Meeting of the Company
the ratification of the appointment of Mr. Nacho Abia as a director.
In Barcelona, on 27 February 2024
Nuria Martín Barnés
Secretary to the Board of Directors |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
|
Grifols, S.A. |
|
|
|
|
By: |
/s/ David I. Bell |
|
|
Name: |
David I. Bell |
|
|
Title: |
Authorized Signatory |
Date: February 27, 2024
Grifols (PK) (USOTC:GIKLY)
Historical Stock Chart
From Apr 2024 to May 2024
Grifols (PK) (USOTC:GIKLY)
Historical Stock Chart
From May 2023 to May 2024